Marjan de Vries1, Dagmar C M Van Rijckevorsel1, Kris C P Vissers2, Oliver H G Wilder-Smith2,3, Harry Van Goor1. 1. Department of Surgery, Radboud University Medical Center, Nijmegen. 2. Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Centre for Sensory-Motor Interaction, Department of Health Sciences, Aalborg University, Aalborg, Denmark.
Abstract
AIM: We aimed to assess the analgesic efficacy, pharmacokinetics, tolerability and safety of a single dose of Δ9-THC in patients with chronic abdominal pain resulting from chronic pancreatitis (CP). METHODS: This was a randomized, single dose, double-blinded, placebo-controlled, two way crossover study in patients suffering from abdominal pain as result of CP (n = 24), post hoc subdivided into opioid and non-opioid users. Δ9-THC (8 mg) or active placebo (5 mg/10 mg diazepam) was administered orally in a double dummy design. RESULTS: No treatment effect was shown for delta VAS pain scores after Δ9-THC compared with diazepam. Δ9-THC was well absorbed with a mean tmax of 123 min. No significant differences were found between Δ9-THC vs. diazepam for alertness, mood, calmness or balance. Feeling anxious and heart rate were significantly increased after Δ9-THC compared with diazepam. The most frequently reported adverse events (AEs) after Δ9-THC administration were somnolence, dry mouth, dizziness and euphoric mood. CONCLUSIONS: A single dose of Δ9-THC was not efficacious in reducing chronic pain resulting from CP, but was well tolerated with only mild or moderate AEs. The PK results in CP patients showed delayed absorption and an increased variability compared with healthy volunteers.
RCT Entities:
AIM: We aimed to assess the analgesic efficacy, pharmacokinetics, tolerability and safety of a single dose of Δ9-THC in patients with chronic abdominal pain resulting from chronic pancreatitis (CP). METHODS: This was a randomized, single dose, double-blinded, placebo-controlled, two way crossover study in patients suffering from abdominal pain as result of CP (n = 24), post hoc subdivided into opioid and non-opioid users. Δ9-THC (8 mg) or active placebo (5 mg/10 mg diazepam) was administered orally in a double dummy design. RESULTS: No treatment effect was shown for delta VAS pain scores after Δ9-THC compared with diazepam. Δ9-THC was well absorbed with a mean tmax of 123 min. No significant differences were found between Δ9-THC vs. diazepam for alertness, mood, calmness or balance. Feeling anxious and heart rate were significantly increased after Δ9-THC compared with diazepam. The most frequently reported adverse events (AEs) after Δ9-THC administration were somnolence, dry mouth, dizziness and euphoric mood. CONCLUSIONS: A single dose of Δ9-THC was not efficacious in reducing chronic pain resulting from CP, but was well tolerated with only mild or moderate AEs. The PK results in CP patients showed delayed absorption and an increased variability compared with healthy volunteers.
Authors: R M Kaufmann; B Kraft; R Frey; D Winkler; S Weiszenbichler; C Bäcker; S Kasper; H G Kress Journal: Pharmacopsychiatry Date: 2009-12-10 Impact factor: 5.788
Authors: Diana H Rintala; Richard Neil Fiess; Gabriel Tan; Sally Ann Holmes; Brian M Bruel Journal: Am J Phys Med Rehabil Date: 2010-10 Impact factor: 2.159
Authors: Marjan de Vries; Dagmar C M van Rijckevorsel; Oliver H G Wilder-Smith; Harry van Goor Journal: Expert Opin Pharmacother Date: 2014-05-12 Impact factor: 3.889
Authors: John Zajicek; Patrick Fox; Hilary Sanders; David Wright; Jane Vickery; Andrew Nunn; Alan Thompson Journal: Lancet Date: 2003-11-08 Impact factor: 79.321
Authors: Pascal H Vuilleumier; Marie Besson; Jules Desmeules; Lars Arendt-Nielsen; Michele Curatolo Journal: PLoS One Date: 2013-03-15 Impact factor: 3.240
Authors: Emily R Perito; John F Pohl; Caitlin Bakker; Matthew A Armfield; Bradley Barth; Addison Cuneo; Maria Mascarenhas; Megha Mehta; Sarah Jane Schwarzenberg Journal: Pancreas Date: 2022-02-01 Impact factor: 3.327